Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development
Toxines Bacteriennes, Institut Pasteur, 75724 Paris, France
*
Author to whom correspondence should be addressed.
Toxins 2021, 13(1), 1; https://doi.org/10.3390/toxins13010001
Received: 10 November 2020 / Revised: 16 December 2020 / Accepted: 17 December 2020 / Published: 22 December 2020
(This article belongs to the Special Issue Selected Papers from the 26th Meeting of the French Society for Toxinology—Bioengineering of Toxins)
Botulinum neurotoxins (BoNTs) show increasing therapeutic applications ranging from treatment of locally paralyzed muscles to cosmetic benefits. At first, in the 1970s, BoNT was used for the treatment of strabismus, however, nowadays, BoNT has multiple medical applications including the treatment of muscle hyperactivity such as strabismus, dystonia, movement disorders, hemifacial spasm, essential tremor, tics, cervical dystonia, cerebral palsy, as well as secretory disorders (hyperhidrosis, sialorrhea) and pain syndromes such as chronic migraine. This review summarizes current knowledge related to engineering of botulinum toxins, with particular emphasis on their potential therapeutic applications for pain management and for retargeting to non-neuronal tissues. Advances in molecular biology have resulted in generating modified BoNTs with the potential to act in a variety of disorders, however, in addition to the modifications of well characterized toxinotypes, the diversity of the wild type BoNT toxinotypes or subtypes, provides the basis for innovative BoNT-based therapeutics and research tools. This expanding BoNT superfamily forms the foundation for new toxins candidates in a wider range of therapeutic options.
View Full-Text
Keywords:
botulinum neurotoxin; Clostridium botulinum; therapeutic application; recombinant toxin; toxin engineering
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Rasetti-Escargueil, C.; Popoff, M.R. Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development. Toxins 2021, 13, 1. https://doi.org/10.3390/toxins13010001
AMA Style
Rasetti-Escargueil C, Popoff MR. Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development. Toxins. 2021; 13(1):1. https://doi.org/10.3390/toxins13010001
Chicago/Turabian StyleRasetti-Escargueil, Christine; Popoff, Michel R. 2021. "Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development" Toxins 13, no. 1: 1. https://doi.org/10.3390/toxins13010001
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit